Theranostics 2014; 4(3):290-306. doi:10.7150/thno.7341


Radiolabeled Nanoparticles for Multimodality Tumor Imaging

Yan Xing 1,2, Jinhua Zhao2, Peter S. Conti 1, Kai Chen 1,✉

1. Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
2. Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See for full terms and conditions.
Xing Y, Zhao J, Conti PS, Chen K. Radiolabeled Nanoparticles for Multimodality Tumor Imaging. Theranostics 2014; 4(3):290-306. doi:10.7150/thno.7341. Available from

File import instruction


Each imaging modality has its own unique strengths. Multimodality imaging, taking advantages of strengths from two or more imaging modalities, can provide overall structural, functional, and molecular information, offering the prospect of improved diagnostic and therapeutic monitoring abilities. The devices of molecular imaging with multimodality and multifunction are of great value for cancer diagnosis and treatment, and greatly accelerate the development of radionuclide-based multimodal molecular imaging. Radiolabeled nanoparticles bearing intrinsic properties have gained great interest in multimodality tumor imaging over the past decade. Significant breakthrough has been made toward the development of various radiolabeled nanoparticles, which can be used as novel cancer diagnostic tools in multimodality imaging systems. It is expected that quantitative multimodality imaging with multifunctional radiolabeled nanoparticles will afford accurate and precise assessment of biological signatures in cancer in a real-time manner and thus, pave the path towards personalized cancer medicine. This review addresses advantages and challenges in developing multimodality imaging probes by using different types of nanoparticles, and summarizes the recent advances in the applications of radiolabeled nanoparticles for multimodal imaging of tumor. The key issues involved in the translation of radiolabeled nanoparticles to the clinic are also discussed.

Keywords: radiolabeled nanoparticles, molecular imaging, multimodality imaging, tumor diagnosis, cancer, theranostics